StockMaster Stephen

This does not constitute investment advice. The market is risky, and investment requires caution. Please make your own independent judgment.

[StockMaster Stephen @Stephen0816_]

Follow me to receive stock signals immediately after the market opens, allowing you to buy at the optimal time and reap substantial profits. Large-cap stocks offer even more opportunities (#NVDA #GOOG...)

My phone number: [phone]

Add me and reply with "7" to find me.

[StockMaster Stephen @Stephen0816_]

#Markets

$PYPL
lost its takeover story overnight. From premium to free-fall. 📉😤

[StockMaster Stephen @Stephen0816_]

Memory is AI’s real bottleneck. $MU HBM sold out to 2027 + multi-year deals after $NVDA warning. Scarcity plays.📈📈

[StockMaster Stephen @Stephen0816_]

#AICloud

$IREN
$4B ARR locked, Horizon 1 live with Microsoft + NVIDIA. AI pivot firing on all cylinders. 🚀

[StockMaster Stephen @Stephen0816_]

After watching this video, I truly realized how terrifying nature can be… A mudslide carrying boulders rushed down, and houses beside it looked like toys.

Humans are so small in the face of nature.

May our friends in Nepal be safe. #StaySafe #NepalFlood

[न B न @Nabin62158820]

पानीको वाहाव यति शक्तिशाली हुन्छ भन्ने मैले जिवन मा कल्पना समेत गरेको थिइन!
#Staysafe #nepal #flood

[StockMaster Stephen @Stephen0816_]

#BHVN

$BHVN Biohaven: SK Biopharma licenses Kv7/opakalim epilepsy platform for up to $795M (incl. ~$400M near-term cash) + royalties. Court awards $4M trade-secret win with Yale. Q2 cash ~$270M, loss narrowed; RISE3 data 2H26 key.

‼️Not advice. DYOR.

[StockMaster Stephen @Stephen0816_]

$EXYN

Q2 rev $0.95M (down YoY on timing), net loss $6.9M. Cash $7.8M but going-concern flagged; up to 3.7M shares for resale. CEO resigned post ~$286k expense probe; interim CEO & new chair in place.

‼️Not investment advice. DYOR.

[StockMaster Stephen @Stephen0816_]

#ANF

Q2: net sales $1.27B (+5% YoY, 15th straight growth quarter), EPS $4.17 (vs ~$1.99 est), boosted by ~$100M tariff refund (~$1.75/share). Operating margin 19.9%. Raised FY guidance to ~5% sales growth & EPS $13.10-$13.60. Stock surged ~36%.

‼️Not investment advice. DYOR.

[StockMaster Stephen @Stephen0816_]

#PLAB

$PLAB
Photronics Q3 beat: Rev $216M (+2.7% YoY) vs $209M est, Adj EPS $0.50 vs $0.40. High-end IC hits record 44%. Q4 guide $207-227M rev, EPS $0.40-0.56. Premarket +18% to ~$34.6. Solid recovery play amid semi design rebound. Buy dips for LT upside to ~$42 tgt.

[StockMaster Stephen @Stephen0816_]

#SDOT

$SDOT(Sadot Group) saw wild swings: debt cleanup via $8 stock swaps fueled 100%+ surge, then -29% to $16.35. AI pivot (TradeOS/TradeIQ) & Nasdaq equity compliance are positives, but zero Q2 revenue, dilution risks, CFO exit & going-concern flags scream caution.

[StockMaster Stephen @Stephen0816_]

#PMI

Composite 56.0 (4yr high), Services 56.8, Mfg 53.2. Growth booming, jobs rising, inflation cooling—supports Q3 GDP near 3%. Nasdaq rebounded on data. Favor quality tech & services over pure cyclicals amid supply delays.

[StockMaster Stephen @Stephen0816_]

#QTTB

$QTTB(Q32 Bio) surged on positive Ph2a SIGNAL-AA data for bempikibart in severe alopecia areata—35.3% mean SALT drop, 40% hit SALT-20. $200M raise funds runway to Ph3 topline. MS initiates OW $34 PT.

[StockMaster Stephen @Stephen0816_]

#ANRO

$ANRO
(Alto Neuroscience) hits new 52-wk high ~$37 on strong momentum. Q2 EPS beat, $338M pro forma cash after $100M raise funds ALTO-207 TRD program thru 2030. PT ~$37-55.

[StockMaster Stephen @Stephen0816_]

#SYRE

$SYRE
(Spyre Therapeutics) stands out. Positive Ph2 SKYLINE data for SPY001/SPY002 in UC show best-in-class potential. SKYWAY enrollment complete; RA data due Sept, more catalysts Q4. $1.15B cash runway to 2029. Stock near highs after strong run. PT $110+.

[StockMaster Stephen @Stephen0816_]

#SYRE

$SYRE
(Spyre Therapeutics) stands out. Positive Ph2 SKYLINE data for SPY001/SPY002 in UC show best-in-class potential. SKYWAY enrollment complete; RA data due Sept, more catalysts Q4. $1.15B cash runway to 2029. Stock near highs after strong run. PT $110+.

[StockMaster Stephen @Stephen0816_]

#ORKA

$ORKA
(Oruka) holds $1.1B cash thru BLA. EVERLAST-B fully enrolled; key data Q3-Q4 2026 + Phase 3 H1’27. Strong PASI100 data, long-acting edge in PsO/HS. Targets $135+.

[StockMaster Stephen @Stephen0816_]

#ELOX

$ELOX
just raised $66M, uplisted to Nasdaq, cash $62M runway to mid-2028. Phase 2b exaluren for nonsense Alport starts Q3’26, data mid-’27. Orphan nod for ADPKD.

[StockMaster Stephen @Stephen0816_]

#HOOD

$HOOD
trading near $95-100 after crypto rally on Trump’s CLARITY Act push & White House summit. Q2: record $1.31B rev (+32%), EPS $0.62 beat. Equities/options/prediction markets offset crypto weakness.

[StockMaster Stephen @Stephen0816_]

#EL

$EL
Q4: sales $3.63B (+6%, organic +5%), adj EPS $0.39 beat Street. FY26 sales +5% to $15B, organic +3%, adj EPS +66% to $2.51. Margins expanding hard on PRGP restructuring. FY27 guide: organic sales 3-5%, adj EPS $3.10-3.35 (above consensus), op margin raised to 12.7-13.5%.

[StockMaster Stephen @Stephen0816_]

#AI

$TWST
surges 22%+ to new 52-wk high after Anthropic taps Twist as independent evaluator for AI protein designs via Claude. Q3 rev +23% to $118M record, guidance raised to $456-457M, Adj EBITDA breakeven eyed in Q4.